CN110464747A - A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid - Google Patents
A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid Download PDFInfo
- Publication number
- CN110464747A CN110464747A CN201910941820.3A CN201910941820A CN110464747A CN 110464747 A CN110464747 A CN 110464747A CN 201910941820 A CN201910941820 A CN 201910941820A CN 110464747 A CN110464747 A CN 110464747A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- ganoderma lucidum
- schisandra chinensis
- quality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 72
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 72
- 235000008422 Schisandra chinensis Nutrition 0.000 title claims abstract description 65
- 240000006079 Schisandra chinensis Species 0.000 title claims abstract description 64
- 239000007788 liquid Substances 0.000 title claims abstract description 59
- -1 al Species 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 54
- 238000010992 reflux Methods 0.000 claims abstract description 26
- 238000000605 extraction Methods 0.000 claims abstract description 24
- 239000012530 fluid Substances 0.000 claims abstract description 20
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 18
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 18
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 18
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 18
- 239000004383 Steviol glycoside Substances 0.000 claims abstract description 13
- 229930182488 steviol glycoside Natural products 0.000 claims abstract description 13
- 235000019411 steviol glycoside Nutrition 0.000 claims abstract description 13
- 150000008144 steviol glycosides Chemical class 0.000 claims abstract description 13
- 235000019202 steviosides Nutrition 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 235000015165 citric acid Nutrition 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 134
- 235000019441 ethanol Nutrition 0.000 claims description 53
- 239000000284 extract Substances 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 235000019640 taste Nutrition 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 235000000404 Poncirus trifoliata Nutrition 0.000 claims 1
- 244000202052 Poncirus trifoliata Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 10
- 230000036039 immunity Effects 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 5
- 241000544066 Stevia Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229930182478 glucoside Natural products 0.000 description 5
- 150000008131 glucosides Chemical class 0.000 description 5
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940100688 oral solution Drugs 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000033065 inborn errors of immunity Diseases 0.000 description 3
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000736075 Schisandra Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100001265 toxicological assessment Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of preparation methods of Schisandra chinensis Ganoderma lucidum oral liquid, raw material includes following component: 140 parts by weight of Schisandra chinensis~170 parts by weight, 100 parts by weight of ganoderma lucidum~140 parts by weight, 0.1 parts by weight of steviol glycoside~0.2 parts by weight, 0.05 parts by weight of citric acid~0.15 parts by weight, 0.2 parts by weight of potassium sorbate~0.5 parts by weight.Preparation method includes: Step 1: refluxing extraction Schisandra chinensis, obtains Schisandra chinensis medical fluid A；Step 2: decocting ganoderma lucidum, ganoderma lucidum medical liquid B is obtained；Step 3: Schisandra chinensis medical fluid A, ganoderma lucidum medical liquid B, steviol glycoside, citric acid and potassium sorbate are mixed, Schisandra chinensis Ganoderma lucidum oral liquid is obtained.The quantity and activity of human immunocyte can be effectively adjusted using Schisandra chinensis Ganoderma lucidum oral liquid prepared by method of the invention, nourishing generate fluid, invigorating qi for tranquilization achieve the purpose that enhance immunity of organisms.
Description
Technical field
The invention belongs to health care product preparation technical fields, and in particular to a kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid.
Background technique
Hypoimmunity refers to human bioequivalence and eliminates external germ, the ability of bacterium reduces, and handles aging, death, change
Property own cells, and mutant cell and virus infected cell ability reduce in identification and processing human body.Hypoimmunity people
Group easily incurs the infection such as bacterium, virus or fungi, liable to illness, and is not easy to restore, and serious person even immune function mistake occurs
It adjusts or immune system is damaged.
It is mainly at present fructus schisandrae glossy ganoderma health-care wine for the Chinese medicine of hypoimmunity, alcoholic content therein is for people
The organs such as body blood and heart have adverse effect, unfavorable for improving the immunity of the human body.
Summary of the invention
Technical problem to be solved by the present invention lies in view of the above shortcomings of the prior art, provide a kind of Schisandra chinensis ganoderma lucidum
The preparation method of oral solution can effectively adjust human immunocyte using Schisandra chinensis Ganoderma lucidum oral liquid prepared by method of the invention
Quantity and activity, nourishing generate fluid, invigorating qi for tranquilization, achieve the purpose that enhance immunity of organisms.
In order to solve the above technical problems, the technical solution adopted by the present invention is that: a kind of preparation of Schisandra chinensis Ganoderma lucidum oral liquid
Method, which is characterized in that raw material includes following component:
140 parts by weight of Schisandra chinensis~170 parts by weight, 100 parts by weight of ganoderma lucidum~140 parts by weight, 0.1 parts by weight of steviol glycoside
~0.2 parts by weight, 0.05 parts by weight of citric acid~0.15 parts by weight, 0.2 parts by weight of potassium sorbate~0.5 parts by weight；
The preparation method comprises the following steps:
Step 1: Schisandra chinensis is placed in the ethanol solution that mass concentration is 60%~80% refluxing extraction 2 times~4 times,
Filtration, merging filtrate, recycling ethyl alcohol simultaneously be concentrated into relative density be 1.10~1.15 medicinal extract, by medicinal extract be cooled to room temperature after with
Water mixing, obtains suspension, takes supernatant to filter after the suspension is stood 20h~30h, obtains medical fluid A；Reflux mentions every time
Taking the quality of ethanol solution used is 4 times~8 times of five tastes protonatomic mass, and the time of each refluxing extraction is 1h~2h；The matter of water
Amount is 6 times~12 times of medicinal extract quality；
Step 2: ganoderma lucidum is added water to cook 2 times~4 times, combined filtrate decompression is concentrated decocting liquid filtration, merging filtrate
The medicinal extract for being 1.10~1.15 to relative density, is cooled to room temperature, mixes with ethanol solution, takes supernatant after standing 20h~30h
Filtration, is recovered under reduced pressure ethyl alcohol, obtains medical liquid B；The quality for decocting water used every time is 10 times~14 times of ganoderma lucidum quality, is decocted every time
The time boiled is 1h~3h；The mass concentration of ethanol solution is 60%~80%, and the quality of ethanol solution is the 1.7 of medicinal extract quality
Times~5 times；
Step 3: medical liquid B described in medical fluid A described in step 1 and step 2 is mixed, to mixing after stevia rebaudianum is added in solution
Glucosides, citric acid and potassium sorbate stir 1h~1.5h, and purified water is added, and stir 1h~1.5h, and filtration is filling, and sterilizing obtains
To Schisandra chinensis Ganoderma lucidum oral liquid.
The preparation method of above-mentioned a kind of Schisandra chinensis Ganoderma lucidum oral liquid, which is characterized in that 160 parts by weight of Schisandra chinensis, ganoderma lucidum
120 parts by weight, 0.15 parts by weight of steviol glycoside, 0.1 parts by weight of citric acid, 0.3 parts by weight of potassium sorbate.
A kind of preparation method of above-mentioned Schisandra chinensis Ganoderma lucidum oral liquid, which is characterized in that the matter of ethanol solution in step 1
Measuring concentration is 70%, and the number of refluxing extraction is 2 times, and the quality of ethanol solution used in each refluxing extraction is hoveniae semoveniae semen and the five tastes
6 times of sub- gross mass, the time of each refluxing extraction are 2h.
The preparation method of above-mentioned a kind of Schisandra chinensis Ganoderma lucidum oral liquid, which is characterized in that ethyl alcohol and dense is recycled in step 1
The pressure of contracting is -0.065MPa~-0.075MPa, and temperature is 75 DEG C.
A kind of preparation method of above-mentioned Schisandra chinensis Ganoderma lucidum oral liquid, which is characterized in that the pressure being concentrated under reduced pressure in step 2
Power is -0.065MPa~-0.075MPa, and temperature is 75 DEG C；Be recovered under reduced pressure in step 2 ethyl alcohol pressure be -0.065MPa~-
0.075MPa, temperature are 65 DEG C.
The preparation method of above-mentioned a kind of Schisandra chinensis Ganoderma lucidum oral liquid, which is characterized in that ethanol solution is dense in step 2
Degree is 70%, and the quality of ethanol solution is 2.5 times of medicinal extract quality.
The parts by weight can for gram, two, jin, the weight meterings unit such as kilogram, ton.
The Schisandra chinensis Ganoderma lucidum oral liquid prepared using method of the invention is used to adjust the quantity and work of human immunocyte
Property, using nourishing generate fluid, invigorating qi for tranquilization as the rules for the treatment of, Schisandra chinensis nourishing generate fluid is selected, ganoderma lucidum adjusts invigorating qi for tranquilization, effectively reaches enhancing
The purpose of immunity of organisms.
Each simple clinical research efficacy effect is as follows in side: Schisandra chinensis, is the drying and ripening of magnoliaceae schisandra
Fruit.Sour, property sweet, warm.Return lung, the heart, kidney channel have astringency inducing, nourishing generate fluid and other effects.
Ganoderma lucidum is the fructification of porous castor section fungi glossy ganoderma, and whole year can adopt, dry in the shade or dry, and has invigorating qi for tranquilization, cough-relieving
Relieving asthma and other effects, it is used for dizziness egersis, shortness of breath and palpitation, consumptive disease cough and asthma.
Compared with the prior art, the present invention has the following advantages:
1, the Schisandra chinensis Ganoderma lucidum oral liquid for using method of the invention to prepare is using Schisandra chinensis and ganoderma lucidum as main ingredient, no other masters
Medicine ingredient, using potassium sorbate as preservative, can effectively adjust human immunocyte's using steviol glycoside and citric acid as flavoring agent
Quantity and activity, nourishing generate fluid, invigorating qi for tranquilization achieve the purpose that enhance immunity of organisms.Steviol glycoside and citric acid can promote
Into miscible, improve antioxygenic property and except raw meat is deodorized, make oral solution have mouthfeel abundant and having assist in the treatment of obesity,
The functions such as diabetes, high blood pressure, heart disease, saprodontia, meanwhile, bacteria breed can be inhibited, promote sucrose inversion, potassium sorbate
Addition can increase the broad-spectrum sterilization of oral solution, improve the effect of oral solution high inhibition mould and spoilage organisms, improve oral
The safety of liquid.
2, method of the invention extracts effective component in Schisandra chinensis using alcohol reflux, using first ganoderma lucidum is added water to cook,
Again with alcohol reflux extraction and boulton process, main component in ganoderma lucidum is extracted, guarantees effective component schizandrin, the five tastes
Sub- ester first and ganoderma lucidum polysaccharide etc. can be fully extracted, utilize, and effectively extract medicinal material on the basis of reducing ethanol solution dosage
In effective component, reduce dose, be conducive to control cost, reduce energy consumption, meanwhile, take boulton process can be compared with low temperature
Extracting solution is recycled under degree, it is ensured that effective component promotes the treatment of Schisandra chinensis Ganoderma lucidum oral liquid not by high temperature in product
Effect and quality.
3, method of the invention will preferably recycle ethyl alcohol and the pressure being concentrated is -0.065MPa~-0.075MPa, and temperature is
75 DEG C, it is capable of forming the characteristics of certain vacuum is spent using reduced pressure, reduces the boiling point of filtrate, increases the heat transfer of explosive evaporation process
Temperature difference, enhanced water evaporation avoid normal pressure thickening temperature is excessively high spice is caused to destroy effective component because heated time is long.
Below with reference to embodiment, technical scheme of the present invention will be described in further detail.
Specific embodiment
Embodiment 1
A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid, raw material includes following component:
Schisandra chinensis 160g, ganoderma lucidum 120g, steviol glycoside 0.15g, citric acid 0.1g, potassium sorbate 0.3g；
The preparation method comprises the following steps:
Step 1: 160g Schisandra chinensis is placed in the ethanol solution that mass concentration is 70% refluxing extraction 2 times, filter, closes
And filtrate, it in pressure is -0.075MPa by combined filtrate, temperature recycles under the conditions of being 75 DEG C and ethyl alcohol and is concentrated into relative density
It for 1.10 39.15g medicinal extract, is mixed after medicinal extract is cooled to room temperature with water, obtains suspension, the suspension is stood for 24 hours
After take supernatant to filter, obtain medical fluid A；The quality of ethanol solution used in each refluxing extraction is 6 times of five tastes protonatomic mass, every time
The time of refluxing extraction is 2h；The quality of water is 10 times of medicinal extract quality；
Step 2: 120g ganoderma lucidum is added water to cook 2 times, decocting liquid filtration, merging filtrate, be in pressure by combined filtrate-
0.065MPa, reduced pressure is the 12.84g medicinal extract that relative density is 1.15 under the conditions of temperature is 75 DEG C, is cooled to room temperature, with second
Alcoholic solution mixing, standing take supernatant to filter afterwards for 24 hours, are -0.075MPa in pressure, second is recovered under reduced pressure under the conditions of being 65 DEG C in temperature
Alcohol obtains medical liquid B；The quality for decocting water used every time is 12 times of ganoderma lucidum quality, and the time decocted every time is 2h；Ethanol solution
Mass concentration be 70%, the quality of ethanol solution is 2.5 times of medicinal extract quality；
Step 3: medical liquid B described in medical fluid A described in step 1 and step 2 is mixed, to mixing after stevia rebaudianum is added in solution
Glucosides 0.15g, citric acid 0.1g, potassium sorbate 0.3g stir 1.5h, and purified water is added to 1000mL, stirs 1h, filters, fill
Dress, every dress 10mL sterilize, and packaging obtains Schisandra chinensis Ganoderma lucidum oral liquid.
Embodiment 2
A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid, raw material includes following component:
Schisandra chinensis 160g, ganoderma lucidum 120g, steviol glycoside 0.15g, citric acid 0.1g, potassium sorbate 0.3g；
The preparation method comprises the following steps:
Step 1: 160g Schisandra chinensis is placed in the ethanol solution that mass concentration is 70% refluxing extraction 2 times, filter, closes
And filtrate, it in pressure is -0.065MPa by combined filtrate, temperature recycles under the conditions of being 75 DEG C and ethyl alcohol and is concentrated into relative density
It for 1.15 39.2g medicinal extract, is mixed after medicinal extract is cooled to room temperature with water, obtains suspension, after the suspension is stood 20h
It takes supernatant to filter, obtains medical fluid A；The quality of ethanol solution used in each refluxing extraction is 6 times of five tastes protonatomic mass, is returned every time
The time that stream extracts is 2h；The quality of water is 10 times of medicinal extract quality；
Step 2: 120g ganoderma lucidum is added water to cook 2 times, decocting liquid filtration, merging filtrate, be in pressure by combined filtrate-
0.075MPa, reduced pressure is the 13.08g medicinal extract that relative density is 1.10 under the conditions of temperature is 75 DEG C, is cooled to room temperature, with second
Alcoholic solution mixing, standing take supernatant to filter afterwards for 24 hours, are -0.065MPa in pressure, second is recovered under reduced pressure under the conditions of being 65 DEG C in temperature
Alcohol obtains medical liquid B；The quality for decocting water used every time is 12 times of ganoderma lucidum quality, and the time decocted every time is 2h；Ethanol solution
Mass concentration be 70%, the quality of ethanol solution is 2.5 times of medicinal extract quality；
Step 3: medical liquid B described in medical fluid A described in step 1 and step 2 is mixed, to mixing after stevia rebaudianum is added in solution
Glucosides 0.15g, citric acid 0.1g, potassium sorbate 0.3g stir 1h, and purified water is added to 1000mL, stirs 1.5h, filters, fill
Dress, every dress 10mL sterilize, and packaging obtains Schisandra chinensis Ganoderma lucidum oral liquid.
Embodiment 3
A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid, raw material includes following component:
Schisandra chinensis 140g, ganoderma lucidum 140g, steviol glycoside 0.2g, citric acid 0.05g, potassium sorbate 0.2g；
The preparation method comprises the following steps:
Step 1: 140g Schisandra chinensis is placed in the ethanol solution that mass concentration is 60% refluxing extraction 3 times, filter, closes
And filtrate, it in pressure is -0.07MPa by combined filtrate, temperature recycles under the conditions of being 75 DEG C and ethyl alcohol and is concentrated into relative density
It for 1.12 34.44g medicinal extract, is mixed after medicinal extract is cooled to room temperature with water, obtains suspension, the suspension is stood into 30h
After take supernatant to filter, obtain medical fluid A；The quality of ethanol solution used in each refluxing extraction is 4 times of five tastes protonatomic mass, every time
The time of refluxing extraction is 1h；The quality of water is 6 times of medicinal extract quality；
Step 2: 140g ganoderma lucidum is added water to cook 3 times, decocting liquid filtration, merging filtrate, be in pressure by combined filtrate-
0.07MPa, reduced pressure is the 15.68g medicinal extract that relative density is 1.12 under the conditions of temperature is 75 DEG C, is cooled to room temperature, with second
Alcoholic solution mixing, takes supernatant to filter after standing 20h, is -0.07MPa in pressure, second is recovered under reduced pressure under the conditions of being 65 DEG C in temperature
Alcohol obtains medical liquid B；The quality for decocting water used every time is 14 times of ganoderma lucidum quality, and the time decocted every time is 1h；Ethanol solution
Mass concentration be 60%, the quality of ethanol solution is 1.7 times of medicinal extract quality；
Step 3: medical liquid B described in medical fluid A described in step 1 and step 2 is mixed, to mixing after stevia rebaudianum is added in solution
Glucosides 0.2g, citric acid 0.05g, potassium sorbate 0.2g stir 1h, and purified water is added to 1000mL, stirs 1.2h, filters, fill
Dress, every dress 10mL sterilize, and packaging obtains Schisandra chinensis Ganoderma lucidum oral liquid.
Embodiment 4
A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid, raw material includes following component:
Schisandra chinensis 170g, ganoderma lucidum 100g, steviol glycoside 0.1g, citric acid 0.15g, potassium sorbate 0.5g；
The preparation method comprises the following steps:
Step 1: 170g Schisandra chinensis is placed in the ethanol solution that mass concentration is 80% refluxing extraction 4 times, filter, closes
And filtrate, it in pressure is -0.065MPa by combined filtrate, temperature recycles under the conditions of being 75 DEG C and ethyl alcohol and is concentrated into relative density
It for 1.14 41.31g medicinal extract, is mixed after medicinal extract is cooled to room temperature with water, obtains suspension, the suspension is stood for 24 hours
After take supernatant to filter, obtain medical fluid A；The quality of ethanol solution used in each refluxing extraction is 8 times of five tastes protonatomic mass, every time
The time of refluxing extraction is 1.5h；The quality of water is 12 times of medicinal extract quality；
Step 2: 100g ganoderma lucidum is added water to cook 4 times, decocting liquid filtration, merging filtrate, be in pressure by combined filtrate-
0.075MPa, reduced pressure is the 10.8g medicinal extract that relative density is 1.15 under the conditions of temperature is 75 DEG C, is cooled to room temperature, with second
Alcoholic solution mixing, takes supernatant to filter after standing 30h, is -0.065MPa in pressure, second is recovered under reduced pressure under the conditions of being 65 DEG C in temperature
Alcohol obtains medical liquid B；The quality for decocting water used every time is 10 times of ganoderma lucidum quality, and the time decocted every time is 3h；Ethanol solution
Mass concentration be 80%, the quality of ethanol solution is 5 times of medicinal extract quality；
Step 3: medical liquid B described in medical fluid A described in step 1 and step 2 is mixed, to mixing after stevia rebaudianum is added in solution
Glucosides 0.1g, citric acid 0.15g, potassium sorbate 0.5g stir 1.2h, and purified water is added to 1000mL, stirs 1h, filters, fill
Dress, every dress 10mL sterilize, and packaging obtains Schisandra chinensis Ganoderma lucidum oral liquid.
In above embodiments, relative density is measured according to 0601 method of " Chinese Pharmacopoeia " general rule, and measuring temperature is 60 DEG C.
The calculating of yield of extract:
The yield of extract of Schisandra chinensis and the yield of extract of ganoderma lucidum in Examples 1 to 4 are calculated, the results are shown in Table 1.
The yield of extract of 1 Examples 1 to 4 of table
| The yield of extract % of Schisandra chinensis | The yield of extract % of ganoderma lucidum | |
| Embodiment 1 | 24.5 | 10.7 |
| Embodiment 2 | 24.5 | 10.9 |
| Embodiment 3 | 24.6 | 11.2 |
| Embodiment 4 | 24.3 | 10.8 |
By table 1, method of the invention can effectively extract the effective component in Schisandra chinensis and ganoderma lucidum, and Fructus Schisandrae Chinensis extractum obtains
Rate 24.3% or more, glossy ganoderma extract yield 10.7% or more, method of the invention can effectively extract in flavour of a drug effectively at
Point, dose is reduced, cost is reduced, reduces energy consumption.
Function test:
Traditional Chinese Medicine Research Institute, Shanxi Province edible cosmetic product examines calibrating center to carry out function to Schisandra chinensis Ganoderma lucidum oral liquid
Test, test are designed according to 5 times of human body recommended amounts (0.5mL/kg.bw), 10 times, 20 times of dosage, i.e. 2.5mL/
Kg.bw, 5mL/kg.bw, 10mL/kg.bw carry out each index determining after continuously feeding to mouse 30 days.
Test result is as follows:
Mice spleen lymphocytes proliferation can be promoted to convert using Schisandra chinensis Ganoderma lucidum oral liquid prepared by method of the invention, mentioned
The delayed allergy ability of high mouse promotes the proliferation of mouse antibodies cellulation, improves the serum hemolysin water of mouse
It is flat；To the body weight increase of mouse, thymus gland/weight ratio, spleen/weight ratio and the mononuclear macrophage of mouse phagocytic function
And NK cell activity has no significant effect, and shows that the Schisandra chinensis Ganoderma lucidum oral liquid of method preparation of the invention has strengthen immunity function
Energy.
Toxicological assessment experiment:
Traditional Chinese Medicine Research Institute, Shanxi Province edible cosmetic product examines calibrating center to carry out toxicity to Schisandra chinensis Ganoderma lucidum oral liquid
Safety evaluatio is learned, specifically includes acute toxicity test, three genetic toxicity tests and 30 days feeding trials, test result is such as
Under:
1, acute toxicity test: rat is given with (2000 times that are equivalent to human body recommended amounts) dosage of 100mL/kgbw
After stomach-filling, it is observed continuously 14 days, the observation period has no that animal has obvious poisoning symptom, no animal dead, and animal is dissected in off-test,
Gross examination of skeletal muscle is shown no obvious abnormalities, and according to acute toxicity grading criteria, rat acute toxicity belongs to nontoxic grade.
2, three genetic toxicity tests: Salmonella reversion test, mouse marrow cell micro nuclear test, mouse inbred strain result
It is feminine gender, shows Schisandra chinensis Ganoderma lucidum oral liquid without mutagenesis.
3, it 30 days feeding trials: (is respectively equivalent to human body to push away with 50mL/kg.bw, 25mL/kg.bw, 12.5mL/kg.bw
Recommend 100 times, 50 times, 25 times of dosage) three dosage groups, separately set solvent control group.Rat continuous gavage 30 days, animal during test
Growth and development it is good, the weight of animals, food-intake, food utilization, hematological indices, the blood biochemical analysis of each dosage group refer to
Mark, organ wet weight and internal organs/weight ratio are compared with solvent control group, and there are no significant for difference (P > 0.05)；Gross anatomy is seen
It examines and has no abnormal change related with sample with histopathological examination, have no that the sample is each to rat within the scope of study dosage
Item observation index generates toxic side effect.
These results suggest that it is safe and non-toxic using Schisandra chinensis Ganoderma lucidum oral liquid prepared by method of the invention, it can trust
It takes.
The above is only presently preferred embodiments of the present invention, not does any restrictions to the present invention, all according to invention skill
Art any simple modification substantially to the above embodiments, change and equivalent structural changes, still fall within the technology of the present invention
In the protection scope of scheme.
Claims (6)
1. a kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid, which is characterized in that raw material includes following component:
140 parts by weight of Schisandra chinensis~170 parts by weight, 100 parts by weight of ganoderma lucidum~140 parts by weight, 0.1 parts by weight of steviol glycoside~
0.2 parts by weight, 0.05 parts by weight of citric acid~0.15 parts by weight, 0.2 parts by weight of potassium sorbate~0.5 parts by weight；
The preparation method comprises the following steps:
Step 1: Schisandra chinensis is placed in the ethanol solution that mass concentration is 60%~80% refluxing extraction 2 times~4 times, filtration,
Merging filtrate recycles ethyl alcohol and is concentrated into the medicinal extract that relative density is 1.10~1.15, mixes after medicinal extract is cooled to room temperature with water
It closes, obtains suspension, take supernatant to filter after the suspension is stood 20h~30h, obtain medical fluid A；Each refluxing extraction institute
With 4 times~8 times that the quality of ethanol solution is five tastes protonatomic mass, the time of each refluxing extraction is 1h~2h；The quality of water is
6 times of medicinal extract quality~12 times；
Step 2: ganoderma lucidum is added water to cook 2 times~4 times, combined filtrate decompression is concentrated into phase by decocting liquid filtration, merging filtrate
The medicinal extract for being 1.10~1.15 to density, is cooled to room temperature, mixes with ethanol solution, takes supernatant to filter after standing 20h~30h
It crosses, ethyl alcohol is recovered under reduced pressure, obtain medical liquid B；The quality for decocting water used every time is 10 times~14 times of ganoderma lucidum quality, is decocted every time
Time be 1h~3h；The mass concentration of ethanol solution is 60%~80%, and the quality of ethanol solution is 1.7 times of medicinal extract quality
~5 times；
Step 3: medical liquid B described in medical fluid A described in step 1 and step 2 is mixed, to mixing after be added in solution steviol glycoside,
Citric acid and potassium sorbate stir 1h~1.5h, and purified water is added, and stir 1h~1.5h, and filtration is filling, and sterilizing obtains the five tastes
Sub- Ganoderma lucidum oral liquid.
2. a kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid according to claim 1, which is characterized in that Schisandra chinensis 160
Parts by weight, 120 parts by weight of ganoderma lucidum, 0.15 parts by weight of steviol glycoside, 0.1 parts by weight of citric acid, 0.3 parts by weight of potassium sorbate.
3. a kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid according to claim 1, which is characterized in that second in step 1
The mass concentration of alcoholic solution is 70%, and the number of refluxing extraction is 2 times, and the quality of ethanol solution used in each refluxing extraction is trifoliate orange
6 times of Dulcis and Schisandra chinensis gross mass, the time of each refluxing extraction are 2h.
4. a kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid according to claim 1 or 2, which is characterized in that step 1
Middle recycling ethyl alcohol and the pressure being concentrated are -0.065MPa~-0.075MPa, and temperature is 75 DEG C.
5. a kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid according to claim 1 or 2, which is characterized in that step 2
The pressure of middle reduced pressure is -0.065MPa~-0.075MPa, and temperature is 75 DEG C；The pressure of ethyl alcohol is recovered under reduced pressure in step 2
For -0.065MPa~-0.075MPa, temperature is 65 DEG C.
6. a kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid according to claim 1 or 2, which is characterized in that step 2
The concentration of middle ethanol solution is 70%, and the quality of ethanol solution is 2.5 times of medicinal extract quality.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910941820.3A CN110464747A (en) | 2019-09-30 | 2019-09-30 | A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910941820.3A CN110464747A (en) | 2019-09-30 | 2019-09-30 | A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110464747A true CN110464747A (en) | 2019-11-19 |
Family
ID=68516947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910941820.3A Pending CN110464747A (en) | 2019-09-30 | 2019-09-30 | A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110464747A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115137789A (en) * | 2021-03-31 | 2022-10-04 | 泸州品创科技有限公司 | Composition for improving sleep function and preparation method and application thereof |
| CN116144446A (en) * | 2021-11-19 | 2023-05-23 | 泸州老窖股份有限公司 | Health care wine for improving sleep function |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109820915A (en) * | 2019-04-01 | 2019-05-31 | 黑龙江双兰星制药有限公司 | The peaceful oral solution of Sugarless type tranquilizing the mind and preparation method thereof for treating neurasthenia, insomnia |
-
2019
- 2019-09-30 CN CN201910941820.3A patent/CN110464747A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109820915A (en) * | 2019-04-01 | 2019-05-31 | 黑龙江双兰星制药有限公司 | The peaceful oral solution of Sugarless type tranquilizing the mind and preparation method thereof for treating neurasthenia, insomnia |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115137789A (en) * | 2021-03-31 | 2022-10-04 | 泸州品创科技有限公司 | Composition for improving sleep function and preparation method and application thereof |
| CN116144446A (en) * | 2021-11-19 | 2023-05-23 | 泸州老窖股份有限公司 | Health care wine for improving sleep function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719498B (en) | A kind of Siberian solomonseal rhizome health-care tea improving immunity and preparation method thereof | |
| CN104337999A (en) | Medicine with lung-moistening cough-relieving efficacy and good mouthfeel and application thereof | |
| CN106072578A (en) | There is the enhancing enzyme composition of immune function of human body, effervescent tablet and preparation method | |
| CN106266898A (en) | A kind of vital energy benefiting and the kidney invigorating, the compound preparation and preparation method thereof of defying age | |
| CN105532998A (en) | Health-care tea containing cordyceps militaris and preparation method thereof | |
| CN104784505B (en) | A kind of Dendrobium officinale health product of auxiliary hyperglycemic and preparation method thereof | |
| CN104138526B (en) | A kind of root of three-nerved spicebush iron sheet ginseng granules agent | |
| CN110464747A (en) | A kind of preparation method of Schisandra chinensis Ganoderma lucidum oral liquid | |
| CN109247560A (en) | A kind of fermented type seasoning rose cooking wine and preparation method thereof | |
| CN101904501B (en) | Functional food for relieving fatigue and preparation method thereof | |
| CN106924548A (en) | The medicine and preparation method of a kind of fatigue-relieving | |
| CN106728387B (en) | Compound medicine with function of promoting immunity and preparation method thereof | |
| CN106309917B (en) | A kind of anti-aging, the compound preparation for preventing cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN107372947B (en) | Tea bag type blood sugar reducing tea and preparation method thereof | |
| CN106418497A (en) | Instant health-care electuary and preparation method thereof | |
| CN107281390A (en) | It is a kind of for Chinese medicine composition of health care and preparation method thereof | |
| CN107019745A (en) | A kind of composition with strengthen immunity function and preparation method thereof | |
| CN104688958A (en) | Drug combination having function of losing weight | |
| CN111480846A (en) | Health-care product for assisting in reducing blood fat and improving immunity | |
| CN104694310A (en) | Grape wine with lipid lowering effect | |
| CN110384238A (en) | A kind of HERBA DENDROBII health care product and HERBA DENDROBII health care product electuary preparation method | |
| CN108721520A (en) | It is a kind of to be used to improve oral solution of immunity and preparation method thereof | |
| CN108277135A (en) | A kind of eucommia health care wine and preparation method | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN107648335A (en) | Adjust the Chinese medicine composition and preparation method of atherosclerosis autophagy and apoptosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191119 |